Archive for April 2022
AARDEX® Group adds etectRx’s Smart Pills to their MEMS® Adherence Hardware ecosystem
The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor smart pill. Liege, Belgium (APRIL 28, 2022) – Belgium-based AARDEX Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s smart pill, the ID-Cap™ System, and AARDEX Group’s MEMS Adherence…
Read MoreExploring the Relationship Between Drug Forgiveness and Patient Adherence
With patient adherence thought to be lower than 50% 1, drug companies are increasingly maximizing dosages to bridge the gap at population scale – but are we overdosing individual patients as a result? The industry’s tendency to always aim for the highest possible dose in the therapeutic window to compensate for missed doses runs the risk…
Read MoreFDA Issues Draft Diversity Guidance to Improve Enrollment of Participants from Underrepresented Patient Populations
Diversity in clinical research is a growing concern for sponsors as many factors can influence how an individual may react to certain drugs: age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background. Thus, if the investigational product is to be scrutinized for safety and efficacy effectively, a diverse population of…
Read MoreOptimizing Study Design to Tackle Protocol Deviations in DCTs
Decentralized Clinical Trials (DCTs) are here to stay, as demonstrated by international regulators’ recent commitments to the model. But while the approach offers a multitude of benefits, from expanding access to increasing cohort diversity, it can also serve to magnify existing protocol deviations such as poor adherence to the dosing regimen. If we are to…
Read MoreHarnessing Digital Health Technology to Bolster Study Power
In a world of big tech, data is king. This slogan is far from news for the Biopharmaceutical Industry, but clinical trials are lengthy, complex, and expensive, meaning precious information isn’t always utilized to its maximum potential. In recent years, a slew of Digital Health Technologies (DHTs), designed to collect and share data remotely, have…
Read MoreAARDEX Industry Insights: Pharma Responds to FDA’s Draft DHT Guidance | EU Clinical Trials Regulation
It’s hard to believe that we are already a full quarter into 2022 – and a busy one it’s been -particularly for the regulatory landscape. AARDEX® Group also announced the first in a series of virtual events, a live panel debate featuring industry adherence experts. More on this and some other key industry happenings below. Industry…
Read More